logo
4th of July Sales Are Already Happening. Here Are the Best Deals Available.

4th of July Sales Are Already Happening. Here Are the Best Deals Available.

New York Times7 hours ago

Michael Murtaugh/NYT Wirecutter
To keep your skin looking dewy and protected, this formula spreads easily without leaving behind a white cast, even on darker skin tones. It goes on like a makeup primer and won't look oily or sticky if reapplied over makeup throughout the day.
Other things to know: Water-resistant up to 40 minutes. Greasy texture (like a watery petroleum jelly) may be off-putting to some. Pricey. This deal doesn't beat the rare single-day 50%-off sale, but it's still a great value. Price reflects in cart with free Bluemercury account.
Read more: The Best Sunscreens for Your Face Supergoop Every. Single. Face. Watery Lotion
This broad-spectrum SPF 50 sunscreen soaks into dry skin to hydrate while it protects. It can also serve as a good primer for dewy makeup looks without being oily or greasy. At just 1.7 ounces, it's not cheap, but one bottle is surprisingly long-lasting.
Other things to know: Very watery. If you prefer a more matte look or have oily skin, this is probably not the sunscreen for you. Sweat-resistant up to 40 minutes. Price reflects in cart; a free Bluemercury account is required for free shipping.
Read more: The Best Sunscreens for Your Face Supergoop Play Everyday Lotion SPF 50 (18 ounces)
Other things to know: Rated SPF 50. None of Wirecutter's testers experienced a white cast, but some reported that it left them feeling greasy. The 18-ounce jug is the most affordable size on a per-ounce basis. Price reflects in cart; a free Bluemercury account is required for free shipping.
Read more: Supergoop Sunscreen Is Worth the Splurge EltaMD Skin Recovery Amino Acid Foaming Cleanser
This cloud-like cleanser feels light, luxurious, and mild on your hands and face. Its sulfate-free soft foam formula fully removes dirt and grime and leaves your face feeling deeply clean but not at all stripped. One pump produces a dollop that's just the right amount for face-washing. $35 $28 from EltaMD
Other things to know: Pretty pricey. 5-ounce bottle. Contains 28 ingredients, making it harder to determine if one of them triggers a sensitivity or irritation. Mostly fragrance-free, with slight hints of coconut and medicine. At the EltaMD site, use promo code SKIN20 to get the deal price.
Read more: The Best Facial Cleansers
Imagine a piece of carry-on luggage with the durability and insulation of a rolling hard cooler. Unlike our top rolling-cooler pick, the Yeti Tundra, the Roadie has a telescoping handle that changes its center of gravity, which may make it easier to maneuver in some situations.
Other things to know: It's in our cooler guide's Competition section, but we like it at a deep discount. Typically pricier than the Tundra, and the difference in maneuverability wasn't immediately clear during tests. Holds 76 cans versus the Tundra's 82. Price reflects in cart.
Read more: The Best Coolers Yeti Camino 35 Carryall Tote
Other things to know: A touch larger than our top pick, but a similar capacity. Its interior pockets are zippered, and zippers don't play well with sand. The smaller-size Camino 20 is also on sale. At REI, membership is required; single-use discount on full-price Yeti item reflects in cart.
Read more: The Best Beach Bag REI Co-op Wonderland 6 Tent
A redesign of REI's beloved Kingdom 6, this is a spacious, wagon-shaped tent with a massive interior and a room-divider for added privacy. The updated pole design has increased stability against wind, the only major weakness of the old model. $500 $350 from REI
Other things to know: Partial fly. No vestibule but an attachable mudroom sold separately. Already-large tent may not be ideal at campsites with limited space. We are still in the process of long-term testing.
Read more: The Best Camping Tents
Connie Park/NYT Wirecutter
With a robust polycarbonate outer shell, aluminum corner guards, and an aluminum frame around the center seam that reinforces the body of the luggage, this isn't just a trunk — it's a traveling fortress. The two TSA locks close with a satisfying latch.
Other things to know: Due to the design, some travelers consider trunks to be easier to pack and to maneuver. Does away with the standard zipper closure. Doesn't have a ton of built-in organization. Lifetime warranty. Use code WIRECUTTER.
Read more: The Best Suitcases for Checking Away The Trunk
This trunk has a clamshell design similar to that of the Monos Hybrid, for a similar price — but it has a zipper, instead of latches. It's available in 14 colors.
Other things to know: Ideal if you prefer zippers over latch closures or you want a trunk to match your other Away luggage. We're fans of Away's luggage generally, but this trunk doesn't feel as robust or satisfying to use as our Monos pick. Enter your email address at the top of the sale page to generate a single-use discount code.
Read more: The Best Suitcases for Checking Osprey Farpoint 40 and Fairview 40 Backpacks
A great starter option for one-bag travel, this backpack is simple to pack and the easiest to carry of all our picks. It's built for travel but designed for hiking, so you'll be comfy on journeys by trail or TSA. $185 $120 from Amazon
With a slightly smaller capacity and lower shoulder straps, the Fairview 40 is a great carry-on backpack for people with smaller torsos. It's just as durable and well made as the Farpoint 40, and the slight design difference doesn't change the fact that it's the easiest bag to carry out of all of our picks.
Other things to know: Backed by Osprey's excellent lifetime warranty. Capacity is a little less spacious than it seems. Laptop and tech gear pocket isn't positioned directly against your back, shifting the center of gravity and making some loads feel heavier than they should. Lifetime warranty. The Fairview is on sale for $1 more at REI.
Read more: The Best Carry-On Travel Backpacks Tommy John Air Mesh Mid-Length Boxer Brief 6" (add five)
Travel can be uncomfortable, but these boxer briefs won't be. Quick-drying, moisture-wicking, and easy to wash on the go, they felt like a fine-tailored garment and moved with the body, scoring higher than any other pair we tested. We loved the front pouch, which lacks seams that can chafe.
Other things to know: Leg length is 6 inches, 2 inches shorter than that of our official pick version, but it's otherwise the same. Fly opens from the top, not the side. Deal price is on five single pairs; add five pairs to cart and use code WCSUMMER.
Read more: The Best Underwear for Travel
Maki Yazawa/NYT Wirecutter
For cooking simple microwave dishes quickly and reheating leftovers well, we like these glass containers. Their airtight, leakproof lids each have a venting knob that you can open or close to capture or release steam as needed, and their rounded metal edges are safe for the microwave. You can store leftovers in the same dish, so cleanup is easy. $60 $45 from Anyday
For college students with dorm microwaves, small-kitchen cooks, or meal-prepping aficionados, this square glass cookware can be great for cooking simple microwave dishes and reheating leftovers, as well as storing food. Each airtight, leakproof lid has a venting knob that you can open or close to capture or release steam as needed. $106 $75 from Anyday
Other things to know: Dishwasher-, oven-, and freezer-safe. Not ideal for developing more-complex flavors. Each set includes two glass containers and their corresponding lids; use promo code WCROUND to get the deal price on the round set or WCSQUARE to get the deal price on the square set.
Read more: These Glass Containers Made Me Hate the Microwave a Little Less Vornado ARA Oscillating Tower Fan
Quiet and reliable, this tower fan has an energy-efficient DC-powered motor that moves air at up to nearly 13 mph on high. It also works as a lamp, providing pleasant and warm ambient lighting. We don't usually like tower fans, but this one surprised us. $250 $190 from Wayfair
Use promo code WIRECUTTER
Other things to know: Expensive. Not easy to clean. Comes with Vornado's reliable five-year warranty. Use promo code WIRECUTTER.
Read more: I've Tested Dozens of Tower Fans. And I Hated Every Single One of Them — Until Now. Windmill AC with WhisperTech
Other things to know: You can't open your window while using it. Typically more expensive than our top pick, and a little louder. Window support bracket not included. You can't control the direction of the fan. Use code WIRECUTTER25 to get the deal price, which includes shipping.
Read more: The Best Air Conditioner Blu Dot Cache Sofa
Generously cushioned, this cute tubular-aluminum-framed outdoor sofa comes fully assembled and built to last (ours from 2021 still looks practically new). The sturdy, rounded cushions are upholstered with durable Sunbrella fabric over a dry-fast, mildew-resistant foam. $4495 $3147 from Blu Dot
Other things to know: The foam can be a little noisy. Cushion covers are not removable, but have been easy to wipe down in our experience. Five-year warranty. Use code WCSUMMER.
Read more: Our Favorite Outdoor Sofas and Chairs Ring Alarm (2nd Generation) 14-piece home security system kit
Reliable and fast, this easy-to-use security system also works with Amazon Alexa and other Ring devices, plus add-ons like cameras. It also offers the biggest bang for your buck when it comes to professional monitoring and 24/7 customer service. $300 $200 from Amazon
Other things to know: Does not include a built-in Eero router, as the Pro model does. Optional Ring Protect Pro monitoring plan is $20 per month. Kit includes one base station, two keypads, eight contact sensors, two motion detectors, and one range extender. Amazon Prime membership required.
Read more: The Best Home Security System
Connie Park/NYT Wirecutter
Linen sheets can be a game-changer for hot sleepers, and our longtime favorite set is durable, breathable, and one of the softest we've tested. The set includes a fitted sheet, a flat sheet, and two pillowcases, but you can also purchase by the piece. $445 $351 from Cultiver
Use promo code WCSUMMER (queen)
Other things to know: Like any linen sheets, these wrinkle easily. More limited sizing than sheets from other brands. No warranty, and a pretty standard 30-day return policy. Deal price is for the queen size, but all sizes are discounted with code WCSUMMER. Street price has risen in recent months.
Read more: The Best Linen Sheets L.L.Bean 280-Thread-Count Pima Cotton Percale Sheet Set (queen)
With a durable construction that only gets softer with each wash, it's no surprise these supple sheets have ranked among our favorites for years. They remain the most crisp and breathable percale sheets we've tested. $169 $144 from L.L.Bean
Other things to know: Percale can feel too textured to those who prefer smooth, drapey sateen sheets. Not Oeko-Tex–certified. Set includes a flat sheet, a fitted sheet, and two pillowcases. One-year return policy. Code WCSUN15 can apply to all sizes, and all sizes qualify for free shipping.
Read more: The Best Cotton Sheets
Connie Park/NYT Wirecutter
Meet the best sub-$50 earbuds we've tried. They have impressive sound and features for the price, as well as an IPX7 dust- and water-resistance rating and high-quality background-noise-reducing microphones that rival those of more expensive models. $40 $26 from Amazon
Other things to know: They lack active noise cancellation and a hear-through mode. Sound quality isn't as balanced as that of our top pick. Use code EAFRE2SF to get the deal. We once saw a $16 lightning deal for these earbuds, but we doubt they'll drop that low again.
Read more: The Best Wireless Bluetooth Earbuds Samsung The Frame QN65LS03DAFXZA LCD TV (2024 model, 65-inch)
Want a TV that isn't just another big black box? The Frame is a great option for people who prefer a living room that doesn't look like it's dedicated to television. Although it resembles a framed piece of art when not in use, it still delivers the same bright, excellent image quality as many of Samsung's upper-tier QLED TVs.
Other things to know: A subscription is necessary to access the full range of art options but not required for regular TV functionality. This is the 2024 model. It comes with a one-year Samsung parts-and-labor limited warranty, and free shipping for Amazon Prime members.
Read more: The Frame Is a Delightful TV That Transforms Into Artwork Eero 6 Wi-Fi router (one unit)
This compact router is easy to set up and smoothly delivers solid internet performance, even while several people are using the connection. It's also one of the easiest routers to hide, on account of its tiny size. You can expand its network by adding Eero extenders or routers or Echo Dot speakers.
Other things to know: Slower overall than our top pick for heavy downloaders and gamers. Most suitable if you're subscribed to a low- to mid-tier internet plan (under 500 Mbps). Two Ethernet ports.
Read more: The Best Wi-Fi Routers
Marki Williams/NYT Wirecutter
Our testers gave these versatile Levi's the highest overall score among straight-leg styles — even over pricey high-end options. They're not only comfy, booty-flattering, well-made, and under $100, but also made in a wide range of sizes and three inseams. The cotton-elastane blend is structured but fits comfortably on the first wear.
Other things to know: Testers with more defined waists found these jeans true to size; others should consider sizing up. Deal available on select washes: Space to Think, Christina, and Neither Here Nor There. Free Red Tab membership required for free shipping.
Read more: The Best Women's Jeans Evelyn Bobbie Defy Bra
This smooth, stretchy bralette actually comfortably supports large breasts without any metal wires, clasps, or sliders — a near-miracle. Its high-back design and seamless edges create smooth contours, the sizing was spot-on, and we like that it's soft enough for lounging and supportive enough for active days. $98 $65 from Evelyn Bobbie
Use promo code WIRECUTTER
Other things to know: Not the cutest, and not ideal for low-cut or strappy tops. Some testers found it too hot and stifling. Not the easiest to pull on. Removable cups may slip out in the wash. Sizes S to 3XL (C to K cup, 30- to 52-inch band). Use code WIRECUTTER.
Read more: The Best, Most Comfortable Bras Harper Wilde Base T-Shirt Bra (pack of three)
A pleasure to wear all day long, this comfy underwire bra creates a smooth, defined silhouette. It's set apart by small details, such as the strap-adjustment sliders' location on the front, which allows the wearer to easily move them up and down without having to reach behind their back.
Other things to know: We wish it came in more sizes beyond 32A to 42F. Straps are thinner than those of our other picks, and for people with heavier breasts, they may dig into the shoulders. Add three bras to cart and use code WCSUMMER to get the discount on the tan, brown, or black color, plus free shipping.
Read more: The Best, Most Comfortable Bras Harper Wilde Bliss Triangle Bralette
The thoughtful details of its wire-free pull-on design and adjustable straps make this comfy bralette tough to beat. The silky, pleasantly stretchy microfiber fits like a second skin, and the plunging neckline and low back work with a variety of tops but still provide ample coverage. $45 $27 from Harper Wilde
Other things to know: Medium support may not be substantial enough if you have heavier, larger breasts. Lacks full nipple coverage. Doesn't provide much shaping. Available in sizes XS to 5XL. On sale in steel and tan with code WCSUMMER.
Read more: The Best, Most Comfortable Bras ThirdLove 24/7 Classic Uplift Plunge Bra
This pretty plunge bra is a sexy, supportive option offering outstanding comfort. It comes with removable push-up pads for a little extra oomph and is available in larger band sizes and half sizes.
Other things to know: May not be supportive enough for larger busts. Sizes AA to H cup (including some half-cup sizes) and 32- to 44-inch band; not every cup size is offered for every band size. On sale in rose dust, amethyst, or coral with code LUV-WIRECUTTER.
Read more: The Best Bras Saxx Non-Stop Stretch Cotton Boxer Brief (pack of three)
Other things to know: Waistband is as close to perfect as we've found, but it rolled in certain situations. Machine-washable. Comes in sizes XS to XXL, with a 5-inch inseam. Use code PR-WCTRAVEL to get the deal price for a three-pack.
Read more: The Best Men's Boxer Briefs
Editor's note: The photo at the top of this article may reflect previous deals that are no longer valid and have been removed. Check out our Deals page for more great discounts on Wirecutter's expert-approved picks.
This article was edited by Janie Campbell and Nathan Burrow. Here's what the Wirecutter Deals team is looking for when they hunt for the best prices on Wirecutter picks every day of the week.
The Wirecutter Deals team breaks down a few simple ways to save money all year long.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Male infertility: 5 lifestyle factors that could be hurting your fertility
Male infertility: 5 lifestyle factors that could be hurting your fertility

Yahoo

time41 minutes ago

  • Yahoo

Male infertility: 5 lifestyle factors that could be hurting your fertility

Medical experts are drawing attention to an often-overlooked aspect of reproductive health during World Infertility Awareness Month: male infertility. While discussions often center on female infertility, about one-third of infertility cases are related to male factors, according to ABC News medical contributor Dr. Alok Patel. "When we think about fertility, there's a lot of focus placed on females," says Patel. "But male issues can include problems with sperm volume or quality, congenital obstructions, infections, and various underlying medical conditions." Several common lifestyle factors can significantly impact male reproductive health. Recent research suggests marijuana use may be associated with impaired male fertility by decreasing sperm volume, affecting sperm morphology and disrupting hormone balance. Patel advises limiting cannabis use when trying to conceive. MORE: Amber Alert issued for missing Idaho teens linked to FLDS group Along with cannabis, alcohol consumption and smoking can be detrimental to fertility. Toxins from smoking, for instance, can directly damage sperm DNA. Physical health plays a crucial role too -- being overweight and having inadequate physical activity can negatively impact fertility. Even high stress levels can affect reproductive health, making stress management an essential consideration. "If you're trying to improve fertility, focus on eating a regular diet, exercising, managing stress, and reducing both cannabis and alcohol use," Patel recommended. "It's also important to have an open conversation with your doctor, especially if you're using substances for medical reasons." Speaking of health management, recent studies have revealed promising developments in other areas of medical science. Research has shown that medications prescribed for individuals with ADHS were associated with lower risks of self-harm and accidents, demonstrating the importance of proper medical treatment in overall safety and well-being. Additionally, for those looking to boost their cognitive function, a new study suggests that strategic power naps might be the answer. German researchers found that short afternoon naps were associated with enhanced problem-solving abilities and creativity -- though Patel advises keeping these naps to 20 to 30 minutes to avoid disrupting nighttime sleep patterns.

Bay Area family shares frustrations after FDA rejects drug for ultra-rare Barth Syndrome
Bay Area family shares frustrations after FDA rejects drug for ultra-rare Barth Syndrome

CBS News

timean hour ago

  • CBS News

Bay Area family shares frustrations after FDA rejects drug for ultra-rare Barth Syndrome

With the FDA recently rejecting a drug application that aims to help those living with Barth Syndrome, one Bay Area family is frustrated by the delay of approved treatments in the rare disease community. Approximately 150 people live with Barth Syndrome nationwide, an ultra-rare genetic disorder that affects only males and impacts muscle and heart muscle health. "He has a severe heart failure, and was admitted to the hospital where he was on intravenous medications to help his heart pump," Megan Branagh, whose son Henry has Barth Syndrome, told CBS News Bay Area. Megan's son was diagnosed with the disease when he was three months old. "There's no treatment or cure for it at all, just simply symptom management," she said. There are currently no FDA-approved therapies for the disease, but Stealth BioTherapeutics has been working for years to get a target drug approved. "Extremely long and delayed," Megan said. "We were supposed to get an answer in January, and FDA asked for a three-month extension based on some data they had requested." The drug, elamipretide, targets cardiolipins, a molecule in the mitochondria that is a key source for the gene defect. It's the only drug for Barth Syndrome clinical trials. After several delays, however, the FDA announced it will not be approving the drug application. Megan believes federal budget cuts could be one of the reasons. "There was only one person left remaining at the FDA who had a hand on our case for this final part of it," she said. "We've heard from the current administration the desire to make medication available for the rare disease community, and the support of the rare disease community. And this case defies everything that has been publicly stated over the last few months." The FDA instead recommended that more data be included in the company's resubmission of the drug application. While the company said they are optimistic for a new path forward with the agency, families like the Branaghs are anxiously waiting for the approval. "Sickening to know that there's something out there that could make a difference that might never be available for Henry or anyone else," she said. Her son is 13 years old and has endured many challenges, taking at least eight pills a day and making frequent trips to the doctor's office. "I do it and I just get it over with," Henry Branagh told CBS News Bay Area. "And I wait six more months, and they usually put a heart monitor for two days and I take it off." He shared that he enjoys playing sports, including baseball, soccer, skiing, and swimming. "I love playing with my friends," Henry said. He added that he does take more frequent breaks to maintain his heart health, and hopes there will be more treatment options for him soon. "It'd be really nice for me to have it too, because my wish is to like live one day be normal without having Barth Syndrome," Henry said. "Mainly when I'm in sports, and I'm running around, and I get tired and other kids are running way faster and have way better stamina." Dr. Hitenda Patel, the Branagh's family cardiologist, told CBS News Bay Area that he doesn't see the application rejection as a denial. "I think the FDA wants a little more data on its efficacy," Patel, who is also the pediatric cardiology director at UCSF Benioff Children's Hospital in Oakland, said. "There are a lot more designer drugs being developed. And designer drugs specifically, are often for rare diseases. And if you only have, let's say, at the most 500 patients in the world, it's very hard to get approval based on the current mandates for the FDA," he added. Patel said FDA approvals in the pediatric rare disease community are an even bigger hill to climb. "It seems like it's a delaying tactic, but I think you have to respect the FDA and its process because it's what has allowed to develop many things," he said. "And ultimately, they are in charge of the safety of the American people." He said that with work from those like the Branagh's do make an impact. "With advocacy such as the Barth Syndrome and what the Branaghs are doing, FDA has realized that there is a huge difference between approval process that is needed for the pediatric and rare disease market as opposed to something that is more common," Patel said. "Because the FDA has its mandates and you have to go through the trial process, it takes a long, long, long time." Patel said he remains optimistic for the community that often gets overlooked. And so, the fight continues for the Branaghs. "Super proud. He inspires us to live our best every moment and take nothing for granted," Henry's mother said. "I think the worst thing to watch as a parent to know that your kid has something that you can't do anything about." She adds that she will continue to fight for his health, no matter how long it takes. "My parents help me out a lot, they just always push me and encourage me to keep on going," Henry said. CBS News Bay Area reached out to Stealth BioTherapeutics, and a spokesperson said that while there is no public timeline yet for next steps, they are working closely with the FDA urgently to reach approval. Meanwhile, the Branaghs are preparing for their next fundraising campaign that will take place at the JBL Ranch on September 27. "Our family started something called Happy Heart Week, that is an awareness and fundraising campaign all around Barth Syndrome. 13 years now, and all the funds go directly to the foundation to support everything that they're doing," she said.

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

Yahoo

timean hour ago

  • Yahoo

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access Only about 2 in 10 eligible patients currently receive cell therapy treatment; today's announcement will reduce unnecessary barriers for patients and providers PRINCETON, N.J., June 27, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi® (lisocabtagene maraleucel; liso-cel) for the treatment of large B cell lymphoma (LBCL) and other lymphomas and Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of multiple myeloma. These label updates reduce certain patient monitoring requirements and remove the Risk Evaluation and Mitigation Strategy (REMS) programs that had been in place since each product was initially approved. Despite the transformative potential of cell therapy, only about 2 in 10 eligible patients receive it, due to the confluence of complex logistical and geographic barriers affecting patients and providers. BMS is committed to a long-term goal of expanding access to cell therapy and supports today's class-wide label updates that will help ease known barriers to treatment and administration while maintaining patient safety. Across both labels, the FDA has approved the reduction or removal of specific patient monitoring requirements for Breyanzi and Abecma. These prolonged requirements posed burdens on healthcare delivery systems and for certain patients and their care partners, particularly those who live far from certified cell therapy treatment centers. The changes include: Driving restrictions reduced from 8 weeks to 2 weeks post treatment Requirement to stay within proximity of a healthcare facility following infusion reduced from 4 weeks to 2 weeks "CAR T cell therapy is a transformational, potentially life-saving option for patients living with blood cancers, and we are working to challenge current practices, assumptions and barriers that limit access," said Lynelle B. Hoch, president, Cell Therapy Organization, Bristol Myers Squibb. "Today's FDA-approved label updates reinforce BMS' continued efforts to collaborate across the healthcare ecosystem, with the ultimate goal of reaching more patients and democratizing access to cell therapy." The FDA has also approved removal of the REMS requirement from each product label. A REMS program is often required to help mitigate known or potential risks associated with new drugs or therapies. The FDA has since determined that the established management guidelines and extensive experience of the medical hematology/oncology community are sufficient to diagnose and manage the risks of side effects, including cytokine release syndrome (CRS) and neurologic toxicities (NTs), without a REMS for the class of CD19- and BCMA-directed autologous CAR T cell therapies. This change is likely to help further accelerate cell therapy into the community center setting. Together, these label updates reflect the growing body of clinical and real-world evidence underpinning the favorable efficacy and safety profile of CAR T cell therapy. To date, more than 30,000 patients have been treated with a CAR T cell therapy, with recent studies, including an analysis BMS presented earlier this month at the ASCO Annual Meeting, showing that the vast majority of serious adverse events (CRS and NTs) occur within the first two weeks of infusion. Following this announcement, BMS will work closely with the more than 150 treatment centers currently approved to administer Breyanzi and Abecma to remove the REMS programs. In parallel, BMS is focused on rapidly expanding the geographic footprint of cell therapy, with a renewed effort to add community cancer centers nationwide to administer Breyanzi and Abecma closer to patients, helping further reduce travel time and duration of stay away from home, family and work. "Living with blood cancer is challenging, but patients and their loved ones still need to maintain jobs, take care of families, and plan for the future," said Sally Werner, chief executive officer, Cancer Support Community. "Today's announcement reduces some of the most onerous requirements that may have previously discouraged patients, particularly those who live far from a treatment center, from seeking the potentially transformational effects of cell therapy. We applaud any and all efforts to continue to break down barriers, reduce time burden on patients and caregivers, and increase uptake of this life-saving therapy." As BMS continues to bring cell therapy to more patients, we are committed to working across the healthcare ecosystem to implement these label updates and continue to design and implement measurable programs to increase uptake and equitable access to cell therapy. For a list of programs and services currently offered to support patients through their BMS cell therapy journey, visit Bristol Myers Squibb: Unlocking the Full Potential of Cell Therapy A pioneer in harnessing the immune system to fight cancer and an established leader in cell therapy, Bristol Myers Squibb is uniquely positioned to unlock the full potential of this technology across blood cancers and within new frontiers, including autoimmune disease. Bristol Myers Squibb is currently the only company with two approved CAR T cell therapies with two distinct targets, available in major markets around the world. Our bold vision for the future is one in which hundreds of thousands of patients can be treated with cell therapy's transformational potential. The building blocks to realize this ambition—a promising and differentiated pipeline, extensive translational and clinical data sets, a deep bench of talent, and robust manufacturing capabilities—are in our cells. We are laser-focused on advancing the field of cell therapy toward a true revolution for patients. Learn more about the science behind cell therapy and ongoing progress at Bristol Myers Squibb here. Breyanzi U.S. FDA-Approved Indications BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have: refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or relapsed or refractory disease after two or more lines of systemic therapy. Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma. adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor. Abecma U.S. FDA-Approved Indication ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Breyanzi U.S. Important Safety Information WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, AND SECONDARY HEMATOLOGICAL MALIGNANCIES Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving BREYANZI. Do not administer BREYANZI to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids. Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving BREYANZI, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with BREYANZI. Provide supportive care and/or corticosteroids as needed. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI. Cytokine Release Syndrome Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. In clinical trials of BREYANZI, which enrolled a total of 702 patients with non-Hodgkin lymphoma (NHL), CRS occurred in 54% of patients, including ≥ Grade 3 CRS in 3.2% of patients. The median time to onset was 5 days (range: 1 to 63 days). CRS resolved in 98% of patients with a median duration of 5 days (range: 1 to 37 days). One patient had fatal CRS and 5 patients had ongoing CRS at the time of death. The most common manifestations of CRS (≥10%) were fever, hypotension, tachycardia, chills, hypoxia, and headache. Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, diffuse alveolar damage, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ensure that 2 doses of tocilizumab are available prior to infusion of BREYANZI. Neurologic Toxicities Neurologic toxicities that were fatal or life-threatening, including immune effector cell-associated neurotoxicity syndrome (ICANS), occurred following treatment with BREYANZI. Serious events including cerebral edema and seizures occurred with BREYANZI. Fatal and serious cases of leukoencephalopathy, some attributable to fludarabine, also occurred. In clinical trials of BREYANZI, CAR T cell-associated neurologic toxicities occurred in 31% of patients, including ≥ Grade 3 cases in 10% of patients. The median time to onset of neurotoxicity was 8 days (range: 1 to 63 days). Neurologic toxicities resolved in 88% of patients with a median duration of 7 days (range: 1 to 119 days). Of patients developing neurotoxicity, 82% also developed CRS. The most common neurologic toxicities (≥5%) included encephalopathy, tremor, aphasia, headache, dizziness, and delirium. CRS and Neurologic Toxicities Monitoring Monitor patients daily for at least 7 days following BREYANZI infusion for signs and symptoms of CRS and neurologic toxicities and assess for other causes of neurological symptoms. Continue to monitor patients for signs and symptoms of CRS and neurologic toxicities for at least 2 weeks after infusion and treat promptly. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated. Manage neurologic toxicity with supportive care and/or corticosteroid as needed. Advise patients to avoid driving for at least 2 weeks following infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic toxicity occur at any time. Hypersensitivity Reactions Allergic reactions may occur with the infusion of BREYANZI. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO). Serious Infections Severe infections, including life-threatening or fatal infections, have occurred in patients after BREYANZI infusion. In clinical trials of BREYANZI, infections of any grade occurred in 34% of patients, with Grade 3 or higher infections occurring in 12% of all patients. Grade 3 or higher infections with an unspecified pathogen occurred in 7%, bacterial infections in 3.7%, viral infections in 2%, and fungal infections in 0.7% of patients. One patient who received 4 prior lines of therapy developed a fatal case of John Cunningham (JC) virus progressive multifocal leukoencephalopathy 4 months after treatment with BREYANZI. One patient who received 3 prior lines of therapy developed a fatal case of cryptococcal meningoencephalitis 35 days after treatment with BREYANZI. Febrile neutropenia developed after BREYANZI infusion in 8% of patients. Febrile neutropenia may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad- spectrum antibiotics, fluids, and other supportive care as medically indicated. Monitor patients for signs and symptoms of infection before and after BREYANZI administration and treat appropriately. Administer prophylactic antimicrobials according to standard institutional guidelines. Avoid administration of BREYANZI in patients with clinically significant, active systemic infections. Viral reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. In clinical trials of BREYANZI, 35 of 38 patients with a prior history of HBV were treated with concurrent antiviral suppressive therapy. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines. Prolonged Cytopenias Patients may exhibit cytopenias not resolved for several weeks following lymphodepleting chemotherapy and BREYANZI infusion. In clinical trials of BREYANZI, Grade 3 or higher cytopenias persisted at Day 29 following BREYANZI infusion in 35% of patients, and included thrombocytopenia in 25%, neutropenia in 22%, and anemia in 6% of patients. Monitor complete blood counts prior to and after BREYANZI administration. Hypogammaglobulinemia B-cell aplasia and hypogammaglobulinemia can occur in patients receiving BREYANZI. In clinical trials of BREYANZI, hypogammaglobulinemia was reported as an adverse reaction in 10% of patients. Hypogammaglobulinemia, either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion, was reported in 30% of patients. Monitor immunoglobulin levels after treatment with BREYANZI and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement as clinically indicated. Live vaccines: The safety of immunization with live viral vaccines during or following BREYANZI treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during BREYANZI treatment, and until immune recovery following treatment with BREYANZI. Secondary Malignancies Patients treated with BREYANZI may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes. Monitor lifelong for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol Myers Squibb at 1-888-805-4555 for reporting and to obtain instructions on collection of patient samples for testing. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. Three of 89 (3%) safety evaluable patients with R/R CLL/SLL developed IEC-HS. Time to onset of IEC-HS ranged from 7 to 18 days. Two of the 3 patients developed IEC-HS in the setting of ongoing CRS and 1 in the setting of ongoing neurotoxicity. IEC-HS was fatal in 2 of 3 patients. One patient had fatal IEC-HS and one had ongoing IEC-HS at time of death. IEC-HS is a life-threatening condition with a high mortality rate if not recognized and treated early. Treatment of IEC-HS should be administered per current practice guidelines. Adverse Reactions The most common adverse reaction(s) (incidence ≥30%) in: LBCL are fever, cytokine release syndrome, fatigue, musculoskeletal pain, and nausea. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, platelet count decrease, and hemoglobin decrease. CLL/SLL are cytokine release syndrome, encephalopathy, fatigue, musculoskeletal pain, nausea, edema, and diarrhea. The most common Grade 3-4 laboratory abnormalities include neutrophil count decrease, white blood cell decrease, hemoglobin decrease, platelet count decrease, and lymphocyte count decrease. FL is cytokine release syndrome. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, and white blood cell decrease. MCL are cytokine release syndrome, fatigue, musculoskeletal pain, and encephalopathy. The most common Grade 3-4 laboratory abnormalities include neutrophil count decrease, white blood cell decrease, and platelet count decrease. Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide. Abecma U.S. Important Safety Information WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS, PROLONGED CYTOPENIA and SECONDARY HEMATOLOGICAL MALIGNANCIES Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with ABECMA. Do not administer ABECMA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids. Neurologic Toxicities, which may be severe or life-threatening, occurred following treatment with ABECMA, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with ABECMA. Provide supportive care and/or corticosteroids as needed. Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) including fatal and life-threatening reactions, occurred in patients following treatment with ABECMA. HLH/MAS can occur with CRS or neurologic toxicities. Prolonged Cytopenia with bleeding and infection, including fatal outcomes following stem cell transplantation for hematopoietic recovery, occurred following treatment with ABECMA. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including ABECMA. Warnings and Precautions: Early Death: In KarMMa-3, a randomized (2:1), controlled trial, a higher proportion of patients experienced death within 9 months after randomization in the ABECMA arm (45/254; 18%) compared to the standard regimens arm (15/132; 11%). Early deaths occurred in 8% (20/254) and 0% prior to ABECMA infusion and standard regimen administration, respectively, and 10% (25/254) and 11% (15/132) after ABECMA infusion and standard regimen administration, respectively. Out of the 20 deaths that occurred prior to ABECMA infusion, 15 occurred from disease progression, 3 occurred from adverse events and 2 occurred from unknown causes. Out of the 25 deaths that occurred after ABECMA infusion, 10 occurred from disease progression, 11 occurred from adverse events, and 4 occurred from unknown causes. Cytokine Release Syndrome (CRS): CRS, including fatal or life-threatening reactions, occurred following treatment with ABECMA. Among patients receiving ABECMA for relapsed refractory multiple myeloma in the KarMMa and KarMMa-3 studies (N=349), CRS occurred in 89% (310/349), including ≥ Grade 3 CRS (Lee grading system) in 7% (23/349) of patients and Grade 5 CRS in 0.9% (3/349) of patients. The median time-to-onset of CRS, any grade, was 1 day (range: 1 to 27 days), and the median duration of CRS was 5 days (range: 1 to 63 days). In the pooled studies, the rate of ≥Grade 3 CRS was 10% (7/71) for patients treated in dose range of 460 to 510 x 106 CAR-positive T cells and 5.4% (13/241) for patients treated in dose range of 300 to 460 x 106 CAR-positive T cells. The most common manifestations of CRS (greater than or equal to 10%) included pyrexia (87%), hypotension (30%), tachycardia (26%), chills (19%), hypoxia (16%). Grade 3 or higher events that may be associated with CRS include hypotension, hypoxia, hyperbilirubinemia, hypofibrinogenemia, ARDS, atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary edema, coagulopathy, renal failure, multiple organ dysfunction syndrome and HLH/MAS. Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension. CRS has been reported to be associated with findings of HLH/MAS, and the physiology of the syndromes may overlap. HLH/MAS is a potentially life-threatening condition. In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS. Of the 349 patients who received ABECMA in clinical trials, 226 (65%) patients received tocilizumab; 39% (135/349) received a single dose, while 26% (91/349) received more than 1 dose of tocilizumab. Overall, 24% (82/349) of patients received at least 1 dose of corticosteroids for treatment of CRS. Almost all patients who received corticosteroids for CRS also received tocilizumab. For patients treated in dose range of 460 to 510 x 106 CAR-positive T cells, 76% (54/71) of patients received tocilizumab and 35% (25/71) received at least 1 dose of corticosteroids for treatment of CRS. For patients treated in dose range of 300 to 460 x 106 CAR-positive T cells, 63% (152/241) of patients received tocilizumab and 20% (49/241) received at least 1 dose of corticosteroid for treatment of CRS. Monitor patients at least daily for 7 days following ABECMA infusion for signs or symptoms of CRS. Continue to monitor patients for signs and symptoms of CRS for at least 2 weeks after infusion. At the first sign of CRS, institute treatment with supportive care, tocilizumab and/or corticosteroids as indicated. Ensure that a minimum of 2 doses of tocilizumab are available prior to infusion of ABECMA. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. Neurologic Toxicities: Neurologic toxicities, including immune-effector cell-associated neurotoxicity (ICANS), which may be severe or life-threatening, occurred concurrently with CRS, after CRS resolution, or in the absence of CRS following treatment with ABECMA. In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, CAR T cell-associated neurotoxicity occurred in 40% (139/349), including Grade 3 in 4% (14/349) and Grade 4 in 0.6% (2/349) of patients. The median time to onset of neurotoxicity was 2 days (range: 1 to 148 days). The median duration of CAR T cell-associated neurotoxicity was 8 days (range: 1 to 720 days) in all patients including those with ongoing neurologic events at the time of death or data cut off. CAR T cell-associated neurotoxicity resolved in 123 of 139 (88%) patients and median time to resolution was 5 days (range: 1 to 245 days). One-hundred and thirty four out of 349 (38%) patients with neurotoxicity had CRS. The onset of neurotoxicity during CRS was observed in 93 patients, before the onset of CRS in 12 patients, and after the CRS event in 29 patients. The rate of Grade 3 or 4 CAR T cell-associated neurotoxicity was 5.6% (4/71) and 3.7% (9/241) for patients treated in dose range of 460 to 510 x 106 CAR-positive T cells and 300 to 460 x 106 CAR-positive T cells, respectively. The most frequent (greater than or equal to 5%) manifestations of CAR T cell-associated neurotoxicity include encephalopathy (21%), headache (15%), dizziness (8%), delirium (6%), and tremor (6%). At the safety update for KarMMa-3 study, one patient developed fatal neurotoxicity 43 days after ABECMA. In KarMMa, one patient had ongoing Grade 2 neurotoxicity at the time of death. Two patients had ongoing Grade 1 tremor at the time of data cutoff. Cerebral edema has been associated with ABECMA in a patient in another study in multiple myeloma. Grade 3 myelitis and Grade 3 parkinsonism have occurred after treatment with ABECMA in another study in multiple myeloma. Monitor patients at least daily for 7 days following ABECMA infusion for signs or symptoms of neurologic toxicities. Continue to monitor patients for signs or symptoms of neurologic toxicities for at least 2 weeks after ABECMA infusion and treat promptly. Rule out other causes of neurologic symptoms. Neurologic toxicity should be managed with supportive care and/or corticosteroids as needed. Counsel patients to seek immediate medical attention should signs or symptoms occur at any time. Advise patients to avoid driving for at least 2 weeks following infusion. Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS): In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, HLH/MAS occurred in 2.9% (10/349) of patients. All events of HLH/MAS had onset within 10 days of receiving ABECMA, with a median onset of 6.5 days (range: 4 to 10 days) and occurred in the setting of ongoing or worsening CRS. Five patients with HLH/MAS had overlapping neurotoxicity. The manifestations of HLH/MAS include hypotension, hypoxia, multiple organ dysfunction, renal dysfunction and cytopenia. In KarMMa-3, one patient had Grade 5, two patients had Grade 4 and two patients had Grade 3 HLH/MAS. The patient with Grade 5 HLH/MAS also had Grade 5 candida sepsis and Grade 5 CRS. In another patient who died due to stroke, the Grade 4 HLH/MAS had resolved prior to death. Two cases of Grade 3 and one case of Grade 4 HLH/MAS had resolved. In KarMMa, one patient treated in the 300 x 106 CAR-positive T cells dose cohort developed fatal multi-organ HLH/MAS with CRS. In another patient with fatal bronchopulmonary aspergillosis, HLH/MAS was contributory to the fatal outcome. Three cases of Grade 2 HLH/MAS resolved. HLH/MAS is a potentially life-threatening condition with a high mortality rate if not recognized early and treated. Treatment of HLH/MAS should be administered per institutional guidelines. Hypersensitivity Reactions: Allergic reactions may occur with the infusion of ABECMA. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) in ABECMA. Infections: ABECMA should not be administered to patients with active infections or inflammatory disorders. Severe, life-threatening, or fatal infections occurred in patients after ABECMA infusion. In all patients receiving ABECMA in the KarMMa and KarMMa-3 studies, infections (all grades) occurred in 61% of patients. Grade 3 or 4 infections occurred in 21% of patients. Grade 3 or 4 infections with an unspecified pathogen occurred in 12%, viral infections in 7%, bacterial infections in 4.3%, and fungal infections in 1.4% of patients. Overall, 15 patients had Grade 5 infections (4.3%); 8 patients (2.3%) with infections of pathogen unspecified, 3 patients (0.9%) with fungal infections, 3 patients (0.9%) with viral infections, and 1 patient (0.3%) with bacterial infection. Monitor patients for signs and symptoms of infection before and after ABECMA infusion and treat appropriately. Administer prophylactic, pre-emptive, and/or therapeutic antimicrobials according to standard institutional guidelines. Febrile neutropenia was observed in 38% (133/349) of patients after ABECMA infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated. Viral Reactivation: Cytomegalovirus (CMV) infection resulting in pneumonia and death has occurred following ABECMA administration. Monitor and treat for CMV reactivation in accordance with clinical guidelines. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against plasma cells. Perform screening for CMV, HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines before collection of cells for manufacturing. Consider antiviral therapy to prevent viral reactivation per local institutional guidelines/clinical practice. Prolonged Cytopenias: In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, 40% of patients (139/349) experienced prolonged Grade 3 or 4 neutropenia and 42% (145/349) experienced prolonged Grade 3 or 4 thrombocytopenia that had not resolved by Month 1 following ABECMA infusion. In 89% (123/139) of patients who recovered from Grade 3 or 4 neutropenia after Month 1, the median time to recovery from ABECMA infusion was 1.9 months. In 76% (110/145) of patients who recovered from Grade 3 or 4 thrombocytopenia, the median time to recovery was 1.9 months. Five patients underwent stem cell therapy for hematopoietic reconstitution due to prolonged cytopenia. The rate of Grade 3 or 4 thrombocytopenia was 62% (44/71) and 56% (135/241) for patients treated in dose range of 460 to 510 x 106 CAR-positive T cells and 300 to 460 x 106 CAR-positive T cells, respectively. Monitor blood counts prior to and after ABECMA infusion. Manage cytopenia with myeloid growth factor and blood product transfusion support according to local institutional guidelines. Hypogammaglobulinemia: In all patients receiving ABECMA in the KarMMa and KarMMa-3 studies, hypogammaglobulinemia was reported as an adverse event in 13% (46/349) of patients; laboratory IgG levels fell below 500 mg/dL after infusion in 37% (130/349) of patients treated with ABECMA. Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion occurred in 45% (158/349) of patients treated with ABECMA. Forty-one percent of patients received intravenous immunoglobulin (IVIG) post-ABECMA for serum IgG <400 mg/dL. Monitor immunoglobulin levels after treatment with ABECMA and administer IVIG for IgG <400 mg/dL. Manage appropriately per local institutional guidelines, including infection precautions and antibiotic or antiviral prophylaxis. Use of Live Vaccines: The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA. Secondary Malignancies: Patients treated with ABECMA may develop secondary malignancies. In KarMMa-3, myeloid neoplasms (four cases of myelodysplastic syndrome and one case of acute myeloid leukemia) occurred in 2.2% (5/222) of patients following treatment with ABECMA compared to none in the standard regimens arm at the time of the safety update. The median time to onset of myeloid neoplasm from ide-cel infusion was 338 days (Range: 277 to 794 days). Three of these five patients have died following the development of myeloid neoplasm. One out of the five cases of myeloid neoplasm occurred after initiation of subsequent antimyeloma therapy. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including ABECMA. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes. Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol Myers Squibb at 1-888-805-4555 for reporting and to obtain instructions on collection of patient samples for testing of secondary malignancy. Adverse Reactions: The most common nonlaboratory adverse reactions (incidence greater than or equal to 20%) include pyrexia, CRS, hypogammaglobulinemia, infections – pathogen unspecified, musculoskeletal pain, fatigue, febrile neutropenia, hypotension, tachycardia, diarrhea, nausea, headache, chills, upper respiratory tract infection, encephalopathy, edema, dyspnea and viral infections. Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at or follow us on LinkedIn, X, YouTube, Facebook and Instagram. Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include whether Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel) for the indications described in this release will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. corporatefinancial-news View source version on Contacts Bristol Myers Squibb Media Inquiries: media@ Investors: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store